Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma

Hematology Reports

Volumn 3, Issue 3 SUPPL., 2011, Pages 10-13

  Luminari, Stefano ^a   Montanini, Antonella ^a   Federico, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Anthracycline; Non hodgkin's lymphoma; Treatment

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG USE; ENCAPSULATION; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LIPOSOMAL DELIVERY; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; SPLENIC MARGINAL ZONE LYMPHOMA; TREATMENT DURATION; TREATMENT PLANNING;

EID: 82755164461     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2011.s3.e4     Document Type: Article

References (29)

1. Luminari S, Cesaretti M, Rashid I, et al. Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematol Oncol 2007;25:189-97.
2. Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998;9:1219-27.
3. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007;25:1916-23.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
5. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41.
6. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-5.
7. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
8. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9: 105-16.
9. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002:346:235-42.
11. Green M. Anthracycline cardiotoxicity, no longer an issue? Ann Oncol 1998;9:691-3.
12. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277-81.
13. Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001:1:278-84.
14. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996;22:483-93.
15. Merli F, Luminari S, Tucci A, et al. R-CHOP vs R-MiniCEOP in elderly patients with diffuse large B-cell lymphoma (B-DLCL) prospectively selected by a multidimensional evaluation scale: preliminary results of a randomized study performed by Intergruppo Italiano Linfomi (IIL). Blood 2007;110:Abs 3429.
16. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130:1-7.
17. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008:CD003917.
18. Ewer MS, Martin FJ, Henderson C, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31:161-81.
19. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposomeencapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14: 239-46.
20. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004;31:5-15.
21. Potchoiba MJ, West M, Smolarek TA, Macaione G, Santacroce E, Lundeen GR. Tissue distribution of doxorubicin in the free and liposomal forms in male Beagles. Proc Am Assoc Cancer Res 1996;37:392: Abs 2675.
22. Federico M, Iannone A, Chan HC, Magin RL. Bone marrow uptake of liposome-entrapped spin label after liver blockade with empty liposomes. Magn Reson Med 1989; 10:418-25.
23. Levine AM, Tulpule A, Espina B, et al. Liposome- encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004;22:2662-70.
24. Tulpule A, Espina BM, Berman N, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non- Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006;7:59-64.
25. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47:2174-80.
26. Rigacci L, Mappa S, Nassi L, et al. Liposome- encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007;25:198-203.
27. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) che - motherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492-9.
28. Rigacci L, Federico M, Martelli M, et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 2003;44:1911-17.
29. Iannitto E, Luminari S, Mammi C, et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL): a GISL study. Blood 2007;110:Abs 1293.